Mineralys Therapeutics Hits New 52-Week High at $40.33, Up 195%

Mineralys Therapeutics, Inc. has reached a significant milestone by hitting a new 52-week high of USD 40.33 on September 18, 2025. This achievement underscores the company's remarkable performance over the past year, with a staggering increase of 195.33%, significantly outpacing the S&P 500's growth of 17.14% during the same period.
Operating within the Pharmaceuticals & Biotechnology sector, Mineralys Therapeutics boasts a market capitalization of USD 2,734 million. Despite its impressive stock performance, the company remains in a loss-making position, reflected in its P/E ratio, which is not applicable. The stock's price-to-book ratio stands at 8.72, indicating a premium valuation relative to its book value.

Additionally, the company has a debt-to-equity ratio of -1.04 and a return on equity of -60.84%, highlighting its current financial structure. With a 52-week low of USD 8.24, the recent high marks a significant turnaround for Mineralys Therapeutics, showcasing its evolving market position within the competitive landscape of the pharmaceuticals and biotechnology industry.